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Long-term, low-grade inflammation does not seem to be a risk fac-tor for venous thromboembolism. The impact of acute inflamma-tion, regardless of cause, on risk of venous thromboembolism is
scarcely studied. We aimed to investigate the impact of acute inflam-
mation, assessed by C-reactive protein, on short-term risk of venous
thromboembolism. We conducted a case-crossover study of patients
with venous thromboembolism (n=707) recruited from a general pop-
ulation. Information on triggers and C-reactive protein levels were
retrieved from hospital records during the 90 days before the event
(hazard period) and in four preceding 90-day control periods.
Conditional logistic regression was used to obtain β coefficients for
change in natural log (ln) transformed C-reactive protein from control
to hazard periods and to determine corresponding odds ratios for
venous thromboembolism. Median C-reactive protein was 107 mg/L in
the hazard period, and ranged from 7 mg/L to 16 mg/L in the control
periods. The level of C-reactive protein was 58% (95% CI 39-77%)
higher in the hazard period than in the control periods.  A one-unit
increase in ln-C-reactive protein was associated with increased risk of
venous thromboembolism (OR 1.79, 95% CI 1.48-2.16). The risk esti-
mates were only slightly attenuated after adjustment for immobiliza-
tion and infection. In stratified analyses, ln-C-reactive protein was
associated with increased risk of venous thromboembolism in cases
with (OR 1.55, 95% CI 1.01-2.38) and without infection (OR 1.77,
95% CI 1.22-2.57).  In conclusion, we found that acute inflammation,
assessed by C-reactive protein, was a trigger for venous thromboem-
bolism.
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Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT)
and pulmonary embolism (PE), is a multicausal disease associated with substantial
morbidity and mortality.1 Contrary to arterial thrombotic disease, there has been
no decline in the incidence of VTE during the last decades.2,3 Thus, there is an
unmet need for improved risk stratification and prevention of VTE.
Chronic inflammation is recognized as part of the pathophysiological process in
arterial thrombosis,4 but its role in venous thrombosis has been less clear.5,6
Inflammatory biomarkers such as high-sensitivity C-reactive protein (hs-CRP) can
predict long-term risk of arterial cardiovascular disease, but have not been associ-
ated with risk of VTE in prospective studies with long-term follow up.7-9 However,
in studies with shorter follow up time, inflammatory markers such as hs-CRP and
neutrophil to lymphocyte ratio were associated with increased risk of VTE.10,11  
Several conditions associated with increased risk of VTE, including cancer, acute
infections, autoimmune diseases and obesity, share the feature of inflammation.12-
15 Even though chronic diseases such as autoimmune dis-
eases carry an increased VTE risk, the risk of VTE is more
pronounced during disease flare-ups, where inflamma-
tion is predominant.14 Acute infection triggers an acute
inflammatory response, and several studies have found
an increased risk of VTE associated with infections.16,17
We have previously investigated the role of infection dur-
ing hospitalization in a case-crossover design, and found
that acute infection was a frequent and strong trigger for
VTE, also after adjustment for immobilization and other
transient risk factors.18 Taken together, this points
towards an association between inflammation and VTE
which is dependent on the degree of the inflammatory
response within a shorter time perspective than as
observed in arterial thrombotic disease. 
The objective of this study was to investigate the role
of acute inflammation, assessed by CRP, as a trigger for
VTE using a case-crossover design. In this study design,
each case serves as his or her own control, and the design
is therefore well suited for studying transient risk fac-
tors.19 We hypothesized that increased CRP, independent
of cause, was a trigger of VTE. 
Methods
For an extensive description of the methods, please see the
Online Supplementary Methods. We conducted a case-crossover
study including all incident VTE cases (n=707) diagnosed among
the participants of the fourth Tromsø Study during 1994-2012.
The study was approved by the regional ethics committee, and
all participants provided informed written consent. A hazard
period of 90 days preceding the incident VTE was compared to
four preceding 90-day control periods. To avoid carry-over
effects, we included a 90-day washout period between the haz-
ard and control periods (Figure 1). For every VTE case, trained
medical personnel searched the hospital medical records for rel-
evant risk factors, diagnostic procedures, surgical and medical
treatment, laboratory test results and diagnoses during hospital
admissions, day care and outpatient clinic visits in any of the
hazard or control periods. We did not have access to medical
records from general practice. A transient risk factor, or trigger,
was defined by its presence during the defined 90-day period. If
an exposure occurred over several days, it was considered to
have occurred if any of the days of exposure fell within the spec-
ified 90-day time period.
CRP was analyzed in serum with a particle-enhanced
immunoturbidimetric assay. CRP measurements from the last
two days before the date of VTE were not included in the analy-
ses to avoid reverse causation, as CRP in these cases could be
caused by an inflammatory response to the VTE itself. If a par-
ticipant had several CRP-measurements during a control or haz-
ard period, the maximum CRP value for each period was used. 
Statistical analyses were carried out using STATA version 14.0
(Stata corporation, College station, Texas, USA). Natural log (ln)
transformation was used for CRP to achieve normal distribu-
tions. Only cases who had their CRP measured in both the haz-
ard and a control period were included in the main analyses.
Since CRP was measured upon request, this would yield the
most conservative risk estimate. We used conditional logistic
regression to obtain β coefficients with 95% confidence intervals
(CI) for change in ln-CRP from control to hazard periods, and to
calculate odds ratios (ORs) with 95% CI per one-unit change in
ln-CRP. The analyses were adjusted for immobilization and
infection in two different models. Further, we performed analy-
ses comparing CRP in the hazard period with each individual
control period, to investigate whether time to event influenced
the association between acute inflammation and VTE. 
In the main analyses, we included only hazard and control
periods in which CRP had been measured. The risk estimates
from this conservative approach could be underestimations, as
subjects with no hospital contact during a hazard or control peri-
od, or with a hospital contact without a CRP measurement,
most likely had a low CRP at that time. To address this concern,
we performed sensitivity analyses where missing CRP values
were set at the lower reported cut-off level of 5 mg/L. We also
performed sensitivity analyses where we included only those
CRP-measurements performed more than seven days before the
date of VTE, to address potential bias due to reverse causation. 
Results
In total, 707 incident VTEs were identified, of which
there were 408 DVTs and 299 PEs (with or without con-
current DVT). The median age at time of VTE-diagnosis
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Figure 1. Case-crossover study design. Relevant risk factors and levels of C-reactive protein were recorded for each case of venous thromboembolism, in the 90-day
hazard period prior to the event and in four preceding 90-day control periods, separated by a 90-day washout period.
was 71 years, and 53.6% were women.  Moreover, 416
(58.8%) VTEs were not related to recent hospitalization,
135 (19.1%) occurred during hospitalization, and 156
(22.1%) were diagnosed within 30 days after hospitaliza-
tion (Table 1). Infection was the most common risk factor
in the hazard period, recorded in 267 (37.8%) of the peri-
ods, followed by immobilization (31.4%), and cancer
(24.3%). The distribution of VTE risk factors and triggers
in the hazard- and control periods are shown in Table 2.
Prophylactic treatment with low-molecular weight
heparin was prescribed in 138 (19.5%) of the 707 hazard
periods, and in 78 (2.8%) of the 2828 control periods. 
In total, after exclusion of hospital contacts the last two
days before VTE-diagnosis, 1283 hospital contacts were
registered during the hazard period and control periods
(Table 3). The number of hospital contacts was higher in
the periods closest to the VTE, increasing from 165, 172,
187 and 199, respectively, in the control periods, to 560
contacts in the hazard period. CRP was measured in 298
cases during the hazard period, and in 75, 72, 86 and 96
cases during the four control periods. Median CRP was
highest in the hazard period (CRP 107 mg/L), and ranged
from 7 mg/L to 16 mg/L in the control periods (Table 3).
Based on β coefficients for ln-CRP obtained from logis-
tic regression analyses, the mean CRP level was 58%
(95% CI 39-77%) higher in hazard than in control peri-
ods. After adjustment for immobilization, the CRP level
was 51% (95% CI 31-70%) higher, and after adjustment
for infection the CRP level was 40% (95% CI 19-61%)
higher in the hazard than in the control periods (Table 4).
This corresponded to a 1.8-fold increased estimated VTE
risk per unit increase in ln-CRP (OR 1.79, 95% CI 1.48-
2.16), which were only slightly attenuated after adjust-
ment for immobilization (OR 1.66, 95% CI 1.37-2.02)
and for infection (OR 1.50, 95% CI 1.21-1.85). 
In analyses stratified for infection, the mean CRP level
was 57% (95% CI 20-94%) higher in the hazard versus
control periods in those without infection and 44% (95%
CI 1-87%) higher in those with infection. Estimated
increase in VTE risk according to a one-unit increase in ln-
CRP was 1.8-fold (OR 1.77, 95% CI 1.22-2.57) in those
without infection and 1.6-fold in those with infection
(OR 1.55, 95% CI 1.01-2.38). Adjustment for immobiliza-
tion revealed similar results (Table 4). 
Sensitivity analyses restricted to CRP measurements
that were conducted more than 7 days before the date of
VTE-diagnosis yielded essentially similar results (Online
Supplementary Table S1). In sensitivity analyses where
missing CRP values were set to 5 mg/L, the estimated
VTE risk per unit increase in ln-CRP was 2.4-fold
increased (OR 2.36, 95% CI 2.14-2.61) (Online
Supplementary Table S2). 
When comparing CRP levels in the hazard period to
each control period (C1-4) separately, there was no trend
for change in CRP level according to time between con-
trol and hazard period (the CRP level was increased by
65%, 77%, 42% and 60%, respectively) (Table 5). The
estimated risk of VTE by ln-CRP was 1.9-fold increased
when comparing the hazard period with C1, 2.2-fold
increased when compared with C2, 1.5-fold increased
when compared with C3, and 1.8-fold increased when
compared with C4.
Discussion
In this case-crossover study including 707 incident
VTEs, we found that acute inflammation, assessed by
increase in CRP, was a trigger for VTE. The association
remained after adjustment for immobilization and for
infection. In stratified analyses, inflammation assessed by
CRP was associated with increased risk of VTE also in
cases without infection. The strength of the estimated
risk of VTE by CRP remained similar when separately
compared to the different control periods. 
Clinically, DVT often presents with the cardinal signs
of inflammation; i.e., redness, swelling, heat, pain and
disturbance of function.  In a case-control study investi-
gating inflammatory markers, patients with DVT had sig-
nificantly higher levels of inflammatory markers, includ-
ing CRP, than controls.20 Based on these results the
authors suggested that inflammation was a consequence
rather than a cause of VTE.  However, the fact that
inflammation is a consequence of VTE does not exclude
the possibility that inflammation can be a cause of the
disease. Previous prospective studies on the association
between inflammation and VTE have shown conflicting
results. In a cohort of healthy men followed for more
than 8 years, baseline hs-CRP was associated with
increased risk of arterial but not venous thrombosis.9
Similarly, two long-term population-based cohorts
reported no association between inflammatory markers
and VTE.7,8 In contrast, studies with shorter follow-up
time have shown an association between CRP and inci-
dent VTE. In a population-based case-cohort study with
515 VTE-cases and 1505 controls, an association between
CRP as a trigger for venous thromboembolism
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Table 1. Characteristics of study participants at the time of venous
thromboembolism (VTE) diagnosis.
Median age; years ± SD 71 ±14
Female sex; n (%) 379 (53.6)
DVT only; n (%) 408 (57.7)
PE+/-DVT; n (%) 299 (42.3)
VTE during hospitalization; n (%) 135 (19.1)
VTE within 30 days after hospitalization; n (%) 156 (22.1)
No hospitalization the last 30 days before VTE; n (%) 416 (58.8)
DVT: deep vein thrombosis, PE: pulmonary embolism.
Table 2. Triggers and risk factors for venous thromboembolism.
Triggers/risk factors Hazard period Control periods
(n=707) (n=2828)a
Infection; n (%) 267 (37.8) 107 (3.8)
Immobilizationb; n (%) 222 (31.4) 57 (2.0)
Cancer; n (%) 172 (24.3) 375 (13.2)c
Surgery; n (%) 118 (16.7) 88 (3.1)
Trauma; n (%) 71 (10.0) 25 (0.9)
Central venous catheter; n (%) 56 (7.9) 17 (0.6)
a707 cases, four control periods for each case; bbedrest ≥3 days, ECOG 4, other immo-
bilizing factor (e.g., wheelchair use); cbased on 106 unique individuals with cancer in
one or more of the control periods.
baseline CRP and VTE was only present in cases suffering
a VTE within the first year after baseline.10 We found a
similar time-dependent pattern between another inflam-
mation marker, the neutrophil to lymphocyte ratio (NLR),
and VTE risk in the Tromsø study cohort.11 There was no
association between NLR and risk of VTE after a median
follow-up time of 17.7 years, but when follow-up time
was restricted to the first 3 years, those with the highest
baseline NLR had a 2.4-fold increased risk of VTE. Taken
together, these studies suggest that acute and augmented
inflammation rather than longstanding, low-grade
inflammation is associated with VTE risk. 
Accordingly, in this case-crossover study, we found that
acute inflammation assessed by CRP was associated with
increased risk of VTE. Acute infection, a strong trigger of
inflammation, is a risk factor for VTE, and higher CRP-
levels are expected in patients with acute infections.16,17,21
After adjustment for infection, and in analyses stratified
for infection, increased serum levels of CRP were still
associated with increased VTE risk, also in cases without
infection. Thus, our findings suggest that inflammatory
responses caused by non-infectious conditions, such as
cancer, surgery, acute medical conditions and trauma, can
partly explain the VTE risk related to these conditions.
Immobilization may accompany these conditions, and
thereby act as a confounder for the observed association.
However, in our study the risk estimates remained essen-
tially similar after adjustment for immobilization. 
The risk of VTE has been shown to be highest the first
two weeks following an infection, and to gradually
decline thereafter.16,17 In our study, there was no trend of a
change in risk estimates according to time between the
hazard and control periods. This further supports that
acute inflammation of short duration is more important
for the VTE risk. Some chronic inflammatory conditions,
such as autoimmune disorders and rheumatic diseases,
also carry increased risk of VTE. However, the risk of VTE
in patients with inflammatory bowel disease, for example,
is especially high during disease flare-ups, where acute
inflammation dominates.22 Furthermore, in a population-
based cohort study on VTE risk in patients with psoriasis
and rheumatoid arthritis (RA), patients with severe psori-
asis and RA-patients in need of a disease modifying anti-
rheumatic drug (DMARD) had higher estimated risk of
VTE than those not prescribed DMARDs.23
Inflammation and coagulation are closely linked.24
Inflammation can be triggered by infection, tissue injury
or tissue stress and malfunction.25 Of these triggers,
inflammation induced by infection has been best charac-
terized. Extensive crosstalk exists between the coagula-
tion and the complement cascades, and complement acti-
vation enhances coagulation through increased tissue fac-
tor (TF) expression and by inhibition of fibrinolysis.26
Anticoagulant activity by the protein C- pathway is
down-regulated by inflammatory cytokines.27 TF expres-
sion increases in response to inflammatory cytokines and
through recruitment from microvesicles and monocytes
induced by P-selectin.28 Activated neutrophils secrete neu-
trophil extracellular traps (NETs), composed of proteins
and decondensed chromatin.29 In addition to an important
role in neutralizing and killing microbes, NETs also con-
tribute to coagulation and platelet aggregation.30 NET for-
mation occurs not only in response to infection, but also
in sterile inflammatory processes and in metastatic can-
cer.30
CRP is an acute-phase protein rapidly synthesized
mainly in the liver under control by inflammatory
cytokines, and CRP levels cease rapidly when the stimuli
for production is diminished.31 CRP has no diurnal varia-
tion, is unaffected by eating, and drugs reducing CRP typ-
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Table 3. Hospital contacts and measurements of C-reactive protein (CRP) in hazard (H) and control periods (C1-C4). H C1
C2 C3 C4
(3-0 months) (18-15 months) (15-12 months) (12-9 months) (9-6 months)
N=707 N=707 N=707 N=707 N=707
Number of hospital contacts 560 165 172 187 199
Number of cases with CRP measurements 298 75 72 86 96
CRPa (mg/L), median (25-perc, 75-perc) 107 (25, 195) 8 (5, 61) 7 (5, 23) 15 (5, 94) 16 (5, 85.5)
aMaximum CRP, with measurements the last two days before date of VTE excluded.
Table 4. Association of C-reactive proteina with risk of venous thromboembolism 
Hazard period compared to control periods 
Adjusted for immobilization Adjusted for infection 
βb (95% CI) βb (95% CI) βb (95% CI)
All cases 0.58 (0.39-0.77) 0.51 (0.31-0.70) 0.40 (0.19-0.61)
Cases with infection 0.44 (0.01-0.87) 0.45 (-0.02-0.92) -
Cases without infection 0.57 (0.20-0.94) 0.57 (0.18-0.96) -
OR (95% CI) OR (95% CI) OR (95% CI)
All cases 1.79 (1.48-2.16) 1.66 (1.37-2.02) 1.50 (1.21-1.85)
Cases with infection 1.55 (1.01-2.38) 1.57 (0.98-2.51) -
Cases without infection 1.77 (1.22-2.57) 1.77 (1.20-2.60) -
OR: odds ratio, CI: confidence interval. aNatural log transformed C-reactive protein. bWhen multiplied by 100, β coefficients can be interpreted as percentage difference compared
with the reference group. 
ically also affect the underlying acute-phase stimulus.31
CRP is commonly used as a marker of inflammation in
clinical practice. Since our study was based on clinical
data, other markers of inflammation and coagulation
were not available as these were only occasionally meas-
ured. CRP is therefore well suited to serve as a marker of
inflammation, a process linked to coagulation through
several pathways as described above. In addition to its
role in innate immunity and complement activation,31
CRP has been found to have prothrombotic effects in
some studies.32-34 Due to methodological issues, especially
the possibility of contamination of CRP preparations
with bacterial lipopolysaccharides, controversy regarding
a direct role of CRP in thrombosis still exists.35
Our study has both strengths and limitations. The case-
crossover design is suitable for studying transient risk fac-
tors, as potential fixed confounders are mainly controlled
for through the design. Further, the VTE-cases were
derived from a large, population-based cohort with high
attendance rate, and all VTE events were symptomatic
and validated. All hospital care in the region is provided
by a single hospital, facilitating the completeness of the
VTE registry. However, some VTE cases might have been
clinically diagnosed and treated without hospital contact,
and some cases of PE presenting as sudden death might
have been misclassified. As each subject serves as his or
her own control, such potential cases would most likely
not affect our results. Our study was limited to informa-
tion from hospital records, as we did not have access to
data from general practice. In most cases, a high CRP
level measured in general practice will increase the likeli-
hood of the patient to be referred to hospital. We cannot
find any reason why hospital referral praxis should differ
in hazard versus control periods. Our data source was the
hospital medical records of VTE-cases, and CRP measure-
ments were made according to each clinician’s prefer-
ence.  As each case serves as his or her own control in the
case-crossover design, only those who had a CRP meas-
urement in both the hazard period and in one or more
control periods were included in the analyses. We can
assume that CRP levels were lower in periods where the
clinician did not find a reason to have CRP measured than
in periods where CRP was measured. As more CRP meas-
urements were done in hazard than in control periods,
this might have diluted the risk estimates. Sensitivity
analyses where missing CRP values were set to 5 mg/L
resulted in higher risk estimates than in the main analy-
ses. We did not adjust for therapeutic agents that could
affect CRP-levels, such as statins, steroids and other
immunosuppressive drugs, as we wanted to investigate
the impact of inflammation on VTE regardless of the
cause of the inflammation. CRP levels measured the last
two days before the date of VTE were omitted to avoid
reverse causation. However, we cannot be certain that
elevated CRP was not caused by the incident VTE more
than two days before the date of VTE diagnosis. To
address this, we performed sensitivity analyses excluding
CRP measurements the last seven days before the date of
VTE-diagnosis, and the results were essentially similar. 
In conclusion, acute inflammation assessed by CRP was
a trigger for VTE in this case-crossover study, also in cases
with inflammatory triggers other than infection.   
CRP as a trigger for venous thromboembolism
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Table 5. Association of C-reactive proteina with risk of venous thromboembolism.
Hazard period (H) compared to individual control periods (C1-C4)
H versus C1 H versus C2 H versus C3 H versus C4
βb (95% CI) βb (95% CI) βb (95% CI) βb (95% CI)
All cases 0.65 (0.22-1.08) 0.77 (0.33-1.20) 0.42 (0.11-0.73) 0.60 (0.30-0.90)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
All cases 1.92 (1.26-2.95) 2.15 (1.39-3.33) 1.52 (1.11-2.08) 1.82 (1.36-2.45)
OR: odds ratio; CI: confidence interval. aNatural log transformed C-reactive protein. bWhen multiplied by 100, β coefficients can be interpreted as percentage difference com-
pared with the reference group.
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